Vitamin D & Fasting: Potential MASLD Treatment in Rats

A new study in rats suggests that both vitamin D supplementation and intermittent fasting may offer therapeutic benefits for metabolic associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). The research, published on February 3, 2026, in Scientific Reports, investigated the effects of these interventions on lipid metabolism, oxidative stress, and inflammatory signaling pathways.

Understanding MASLD

MASLD is a growing global health concern, characterized by the accumulation of fat in the liver, inflammation, and impaired metabolic function. It’s closely linked to obesity, type 2 diabetes, and cardiovascular disease. The condition can progress to more severe liver damage, including cirrhosis and liver failure.

The Rat Study Design

Researchers at Mansoura University in Egypt, along with collaborators from other institutions, divided 24 male Sprague-Dawley rats into four groups. The groups consisted of a control group, a group fed a high-fat and fructose diet to induce MASLD, a group fed the high-fat diet supplemented with vitamin D, and a group fed the high-fat diet with intermittent fasting. The study focused on several key indicators of liver health and metabolic function.

Key Findings: Improvements in Liver Health

Both vitamin D and intermittent fasting demonstrated significant improvements in several markers of liver health. Specifically, both interventions led to reductions in liver enzymes ALT and AST, indicators of liver damage. Vitamin D reduced ALT by 42% and AST by 38%, while intermittent fasting lowered ALT by 47% and AST by 45%, compared to the rats on the high-fat diet alone. These findings suggest a protective effect against liver cell injury.

Impact on Lipid Metabolism

The study also revealed positive effects on lipid profiles. Both vitamin D and intermittent fasting led to decreases in triglycerides and LDL-cholesterol (often referred to as “bad” cholesterol), and increases in HDL-cholesterol (“good” cholesterol). Triglycerides and LDL-C were reduced by 31-48% across the two intervention groups, while HDL-C increased by 18-24%. These changes indicate an improvement in how the body processes and manages fats.

Reducing Oxidative Stress

Oxidative stress, an imbalance between the production of free radicals and the body’s ability to neutralize them, plays a role in the development of MASLD. The research showed that both vitamin D and intermittent fasting helped to mitigate oxidative stress. Vitamin D reduced levels of MDA (a marker of lipid peroxidation, indicating oxidative damage) by 36%, while intermittent fasting reduced MDA by 54%. Concurrently, both interventions increased levels of GSH (glutathione), a key antioxidant, by 61% with vitamin D and 82% with intermittent fasting.

Modulating Inflammatory Pathways

Inflammation is a central feature of MASLD. The study investigated the impact of vitamin D and intermittent fasting on key inflammatory signaling pathways. Both treatments were found to downregulate hepatic expression of SREBP1, a protein involved in fat synthesis, and AQP9, a glycerol transport pathway. Importantly, both interventions also suppressed the activation of TLR4/NF-κB signaling, a major inflammatory pathway implicated in MASLD progression.

What Which means for Humans

While these findings are promising, it’s crucial to remember that this research was conducted in a rat model. Further studies are needed to determine whether similar benefits can be observed in humans. The researchers emphasize that vitamin D and intermittent fasting may represent complementary, non-pharmacological strategies for managing MASLD, but they are not a substitute for conventional medical care.

The study supports the growing body of evidence suggesting that lifestyle interventions can play a significant role in preventing and managing metabolic diseases. Vitamin D is known for its anti-inflammatory and insulin-sensitizing properties, while intermittent fasting has been shown to improve metabolic health and energy balance. The combination of these approaches may offer a synergistic effect in addressing MASLD.

Looking Ahead

The authors of the study call for further translational investigation to explore the potential of vitamin D and intermittent fasting in human populations with MASLD. Future research should focus on determining optimal dosages of vitamin D, appropriate intermittent fasting protocols, and identifying individuals who are most likely to benefit from these interventions. Understanding the underlying mechanisms by which these interventions exert their effects will also be crucial for developing more targeted and effective therapies for MASLD.